Nonhuman primate models for evaluation of AIDS therapy.
Infection of macaque monkeys with simian immunodeficiency virus (SIV) has been established as an excellent animal model system for studying the pathogenesis of an HIV-like virus and for evaluating newly developed antiretroviral drugs and vaccines. Based on their genetic, antigenic, and biologic properties, the simian immunodeficiency viruses are the closest known relatives of the human AIDS viruses, and experimental infection of macaque monkeys results in a disease that is remarkably similar to human AIDS. Infected macaques show diarrhea, weight loss, hematologic abnormalities including lymphopenia and thrombocytopenia, lymphadenopathy/lymphoid hyperplasia that progresses to lymphoid depletion, immunosuppression with marked reduction in CD4+ cells and in the CD4+/CD8+ cell ratio, and opportunistic infections. A majority of such macaques die from an AIDS-like disease within one to three years of infection. An acutely lethal variant of SIV has been identified that results in death in susceptible macaques within 7-12 days of infection. Preliminary prophylactic treatment trials with AZT in macaque monkeys exposed to the acutely lethal SIV variant indicate that some protection is provided when AZT treatment is initiated within 24 hours of virus exposure. Other studies with the more chronic SIV infection model, however, failed to show any prophylactic efficacy of CS-87, AZT, D4T, or FDT.
McClure
H M
HM
Yerkes Regional Primate Research Center, School of Medicine, Emory University, Atlanta, Georgia 30322.
Anderson
D C
DC
Ansari
A A
AA
Fultz
P N
PN
Klumpp
S A
SA
Schinazi
R F
RF
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D002520:Cercopithecidae; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D000882:Haplorhini; D006801:Humans; D008251:Macaca; D016097:Simian Acquired Immunodeficiency Syndrome / Q000188:drug therapy*
D000998:Antiviral Agents